America has a weight problem – over 40% of the US is obese and over 70% are overweight. Diet and exercise are the cornerstones of treatment; however, new medications are coming to the market. The recent STEP Trial evaluated injectable semaglutide for weight loss. This course will evaluate the trial and if there is now an easy step in weight loss.

Upon successful completion of this application-based course, pharmacists and pharmacy students should be able to:
1. Describe the mechanism of action and clinical pearls of semaglutide
2. Compare and contrast semaglutide with other available glucagon-like peptide-1 receptor agonists
3. Discuss clinical trial data on semaglutide’s effect on weight outcomes
4. Identify patients who are candidates to receive semaglutide for weight loss
5. Develop a conclusion for the clinical appropriateness of care based on a clinical trial

Abby Winter, PharmD, MPA, BCACP
Clinical Assistant Professor
University of Washington

Abby Winter does not report any actual or potential conflicts of interest in relation to this continuing pharmacy education course. 

Off-label use of medications will be discussed during this course.

To obtain 1 contact hour of continuing pharmacy education credit (0.1 CEU), participants must read:

Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567185.

*CEimpact provides you with two (2) opportunities to complete the exam. If there are two failed attempts, the participant will not receive CPE credit.

Fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: November 10, 2021
Planned Expiration Date: November 10, 2024